Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

Table 3

Response to treatment.

Enrolled patients	43
Biochemical response
PSA decline ≥50%	27 (62.8%)
Stable disease	9 (20.9%)
Progressive disease	7 (16.3%)
Objective response
Partial remission	8/17 (47.1%)
Stable disease	7/17 (41.1%)
Progressive disease	2/17 (11.8%)
Palliative response	31 (72.1%)